TOP TEN perturbations for 38495_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38495_s_at
Selected probe(set): 214088_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38495_s_at (214088_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

esophageal squamous cell carcinoma study 1 / normal esophageal epithelium sample

Relative Expression (log2-ratio):-3.9602804
Number of Samples:8 / 18
Experimental esophageal squamous cell carcinoma study 1
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy.
Control normal esophageal epithelium sample
Histologically normal esophageal squamous cell epithelium biopsy samples from patients that were investigated for esophageal pain, but diagnosed as healthy.

keratinocyte differentiation study 2 (KLF4 siRNA) / keratinocyte differentiation study 2

Relative Expression (log2-ratio):-3.421507
Number of Samples:2 / 2
Experimental keratinocyte differentiation study 2 (KLF4 siRNA)
KLF4 (Kruppel-like factor 4) depleted primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. KLF4 depletion was done using siRNAs: KLF4i(A): CCGAGGAGTTCAACGATCT; KLF4i(B): TGACCAGGCACTACCGTAA. Differentiation was induced at 100% confluency.
Control keratinocyte differentiation study 2
Primary neonatal keratinocytes differentiated with 1.2 mM calcium for 3 days. Keratinocytes obtained from freshly isolated foreskin were grown in keratinocyte-SFM medium supplemented with epidermal growth factor and bovine pituitary extract. Differentiation was induced at 100% confluency.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (subconfluent)

Relative Expression (log2-ratio):2.9858408
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (subconfluent)
Subconfluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 1-2 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells still grew dispersed in the culture insert and covered 70% of the insert.

diabetes type 2 study 27 (LCM) / diabetes type 2 study 27 (enzymatic)

Relative Expression (log2-ratio):-2.9022474
Number of Samples:34 / 19
Experimental diabetes type 2 study 27 (LCM)
Pancreatic islet samples obtained from type 2 diabetic (T2D) phenotyped pancreatectomized patients (PPP) and isolated by laser capture microdissection (LCM). Islets specimens were retrieved by LCM from snap-frozen surgical specimen from patients who underwent pancreatectomy for pancreatic diseases. Histopathology of the resected tissue did not reveal insulitis in any PPP. Patients age <18 years were excluded. Patients with type 2 diabetes had fasting glycemia ≥7.0 mmol/l; HbA1C ≥6.5% and history of diabetes for >1 year.
Control diabetes type 2 study 27 (enzymatic)
Pancreatic islet samples obtained from type 2 diabetic (T2D) patients and isolated by enzymatic digestion. Well-preserved islets were isolated by collagenase digestion of pancreas from brain-dead organ donors which suffered from type 2 diabetes. After 2±1 days of culture, islets were successfully hand-picked and processed for further analyses. Type 2 diabetes was diagnosed based on clinical history, treatment with glucose-lowering drugs, and lack of anti-GAD65 autoantibodies.

Barrett's esophagus study 3 / esophageal squamous cell carcinoma study 1

Relative Expression (log2-ratio):2.89472
Number of Samples:17 / 8
Experimental Barrett's esophagus study 3
Esophageal epithelium samples from areas with Barrett's esophagus metaplasia which were recovered by laser capture microdissection.
Control esophageal squamous cell carcinoma study 1
Esophageal squamous cell carcinoma (ESCC) biopsy samples from chemotherapy-naive patients with histological grading G1 (well differentiated) and UICC stage II and III, which undergone esophagectomy.

bronchial epithelial cell differentiation study 1 (day28) / bronchial epithelial cell differentiation study 1 (confluent)

Relative Expression (log2-ratio):2.8667946
Number of Samples:3 / 3
Experimental bronchial epithelial cell differentiation study 1 (day28)
Differentiated normal human bronchial epithelial cell (NHBE) cultured for 28 days in an air-liquid interface (ALI) system. At this time point cells were fully differentiated and formed a polarized, pseudostratified mucociliary epithelium. In order to generate the ALI culture, undifferentiated cells were grown under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. When cells reached confluency (after 3-5 days), an air-liquid interface culture (ALI system) was created by removing the apical medium and replacing the medium of the basal compartment with B-ALI differentiation medium. During the 28 days culture medium was replaced every 48 hour.
Control bronchial epithelial cell differentiation study 1 (confluent)
Confluent undifferentiated normal human bronchial epithelial cell (NHBE) cultured for 3-5 days under submerged conditions in bronchial air-liquid interface (B-ALI) growth basal medium supplemented with expansion media. At this time point cells formed a monolayer covering the whole surface of the insert.

psoriasis study 25 (lesional; baseline; ustekinumab; responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; responder)

Relative Expression (log2-ratio):2.7298641
Number of Samples:22 / 23
Experimental psoriasis study 25 (lesional; baseline; ustekinumab; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; ustekinumab; responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder) / psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder)

Relative Expression (log2-ratio):2.7220497
Number of Samples:22 / 23
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (non-lesional; baseline; ustekinumab; 90mg; responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 25 (lesional; baseline; ustekinumab; non-responder) / psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)

Relative Expression (log2-ratio):2.6800385
Number of Samples:10 / 9
Experimental psoriasis study 25 (lesional; baseline; ustekinumab; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 25 (non-lesional; baseline; ustekinumab; non-responder)
Non-lesional and macroscopic normal skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

psoriasis study 24 (lesional; ustekinumab; 12wk; 90mg; responder) / psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder)

Relative Expression (log2-ratio):-2.6700926
Number of Samples:18 / 22
Experimental psoriasis study 24 (lesional; ustekinumab; 12wk; 90mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at 12 week after treatment with 90 mg ustekinumab and assigned as responders. Ustekinumab was administered subcutaneously in dose of 90 mg at week 0 and 4. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT. ATC code:
Control psoriasis study 24 (lesional; baseline; ustekinumab; 90mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 90 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.